Japan’s Shionogi says COVID treatment did not meet endpoint in late-stage trial
Shionogi said previously it expected the pill, known commercially as Xocova, to deliver $2 billion in annual sales if it secured U.S. approval.
If you are not happy with the results below please do another search
Shionogi said previously it expected the pill, known commercially as Xocova, to deliver $2 billion in annual sales if it secured U.S. approval.
Their investment pledges came as President Emmanuel Macron prepared to kick off today’s annual ‘Choose France’ event aimed at wooing big overseas businesses and investors.
The Biden administration is expected to issue new tariffs on Chinese-made medical devices like syringes and personal protective equipment when it unveils its new trade strategy next week, according to two sources familiar with the decision.
Bluebird bio released its first-quarter 2024 business report on Thursday, touting a nearly 140% year-over-year increase in revenue amid the growing uptake of its three gene therapies.
MacroGenics’ stock dropped by as much as 70% Friday morning after the biotech disclosed five deaths in the Phase II TAMARACK trial for its investigational antibody-drug conjugate vobramitamab duocarmazine in metastatic castration-resistant prostate cancer.
Sanofi announced a deal worth up to $1.4 billion with Novavax on Friday for its COVID-19 vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business.
The 2024 American Society of Gene & Cell Therapy annual meeting attracted a record number of attendees and abstracts, testimony to the tremendous growth of the cell and gene therapy industry. But for me, my week onsite in Baltimore laid bare the major challenges that stand between cell and gene therapies (CGTs) and the masses.
The U.S. drug regulator has pushed back its decision on Moderna’s (MRNA.O) respiratory syncytial virus (RSV) vaccine due to “administrative constraints” and will complete the review by the end of this month, the company said on Friday.
Survey of life sciences experts found 70% recognize potential for AI, but many are struggling to get started or implement it at scale due to challenges including data integrity and interoperability.
IPG Health today announced the next evolution of its unmatched global offering after launching successfully nearly three years ago. Doubling down on the connectivity and interoperability that have powered meteoric growth, the network is further integrating some of its already closely aligned agencies to fuel the next era of innovation and impact.